查看文章

Neutropenia is a common side effect of myelosuppressive chemotherapy. Administration of granulocyte colonystimulating factor is being used for neutropenia prophylaxis, but there are patients who develop neutropenia or febrile neutropenia despite prophylaxis. We attempted to identify potential risk factors for chemotherapyinduced neutropenia in patients with pegfilgrastim prophylaxis.

This was a singlecenter, retrospective, observational study of patients with breast cancer or diffuse large Bcell lymphoma. We obtained patients’ data from electronic medical records, including baseline demographics and clinical characteristics regarding diseases, treatments and laboratory values. The outcome measures assessed were the incidence of neutropenia and febrile neutropenia.

There were a total of 127 patients, including 77 patients with diffuse large Bcell lymphoma (DLBCL) and 50 …